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Abstract
Mutations in BRCA1 and BRCA2 cause deficiencies in homologous recombination repair
(HR), resulting in repair of DNA double-strand breaks by the alternative non-homologous
end-joining pathway, which is more error prone. HR deficiency of breast tumors is important
because it is associated with better responses to platinum salt therapies and PARP inhibi-
tors. Among other consequences of HR deficiency are characteristic somatic-mutation sig-
natures and gene-expression patterns. The term “BRCA-like” (or “BRCAness”) describes
tumors that harbor an HR defect but have no detectable germline mutation in BRCA1 or
BRCA2. A better understanding of the genes and molecular events associated with tumors
being BRCA-like could provide mechanistic insights and guide development of targeted
treatments. Using data from The Cancer Genome Atlas (TCGA) for 1101 breast-cancer
patients, we identified individuals with a germline mutation, somatic mutation, homozygous
deletion, and/or hypermethylation event in BRCA1, BRCA2, and 59 other cancer-predispo-
sition genes. Based on the assumption that BRCA-like events would have similar down-
stream effects on tumor biology as BRCA1/BRCA2 germline mutations, we quantified these
effects based on somatic-mutation signatures and gene-expression profiles. We reduced
the dimensionality of the somatic-mutation signatures and expression data and used a sta-
tistical resampling approach to quantify similarities among patients who had a BRCA1/
BRCA2 germline mutation, another type of aberration in BRCA1 or BRCA2, or any type of
aberration in one of the other genes. Somatic-mutation signatures of tumors having a non-
germline aberration in BRCA1/BRCA2 (n = 80) were generally similar to each other and to
tumors from BRCA1/BRCA2 germline carriers (n = 44). Additionally, somatic-mutation sig-
natures of tumors with germline or somatic events in ATR (n = 16) and BARD1 (n = 8)
showed high similarity to tumors from BRCA1/BRCA2 carriers. Other genes (CDKN2A,
CTNNA1, PALB2, PALLD, PRSS1, SDHC) also showed high similarity but only for a small
number of events or for a single event type. Tumors with germline mutations or hypermethy-
lation of BRCA1 had relatively similar gene-expression profiles and overlapped considerably
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with the Basal-like subtype; but the transcriptional effects of the other events lacked consis-
tency. Our findings confirm previously known relationships between molecular signatures
and germline or somatic events in BRCA1/BRCA2. Our methodology represents an objec-
tive way to identify genes that have similar downstream effects on molecular signatures
when mutated, deleted, or hypermethylated.
Introduction
Approximately 1–5% of breast-cancer patients carry a pathogenic germline variant in either
BRCA1 or BRCA2 [1–5]. These genes play important roles in homologous recombination
repair (HR) of double-stranded breaks and stalled or damaged replication forks [6, 7]. When
the BRCA1 or BRCA2 gene products are unable to perform HR, cells may resort to non-
homologous end-joining, a less effective means of repairing double-stranded breaks, poten-
tially leading to an increased rate of DNA mutations [8–11]. Patients who carry biallelic loss of
BRCA1 and BRCA2 due to germline variants and/or somatic events often respond well to poly
ADP ribose polymerase (PARP) inhibitors and platinum-salt therapies, which increase the rate
of DNA damage, typically causing the cells to enter programmed cell death [12–17].
The downstream effects of BRCA mutations are distinctive. For example, BRCA-mutant
tumors exhibit an abundance of C-to-T transitions across the genome, potentially reflecting
tumor cells’ impaired ability to repair specific types of DNA damage [18]. In large-scale
sequencing projects, such mutational patterns (termed “somatic-mutation signatures”) have
been observed in association with other types of molecular events, as well as environmental
and endogenous exposures, across many cancer types [19, 20]. Among these signatures, the
so-called “Signature 3” has been associated with BRCA mutations and HR [19, 21].
Other downstream effects of BRCA mutations include characteristic transcriptional
responses. For example, it has been shown that the “Basal” gene-expression subtype is enriched
for tumors with BRCA1 mutations [22–25], that BRCA1 mutations are commonly found in tri-
ple-negative breast tumors [26, 27], and that gene-expression profiles may predict PARP
inhibitor responses [28, 29]. These patterns are consistently observable, even in the presence of
hundreds of other mutations [25, 30].
In 2004, Turner, et al. coined the term “BRCAness” to describe patients who do not have a
pathogenic germline variant in BRCA1 or BRCA2 but who have developed a tumor with an
impaired ability to perform HR [31]. Here we use the alternative term “BRCA-like.” This cate-
gory may be useful for clinical management of patients and especially for predicting treatment
responses [31, 32]. Recent estimates suggest that the proportion of breast-cancer patients who
fall into this category may be as high as 20% [33]. Davies, et al. demonstrated an ability to cate-
gorize patients into this category with high accuracy based on high-level mutational patterns
[33]. Polak, et al. confirmed that somatic mutations, large deletions, and DNA hypermethyla-
tion of BRCA1 and BRCA2 are reliable indicators of being BRCA-like [21, 34–36]. They also
showed a relationship between being BRCA-like and germline mutations in PALB2 and hyper-
methylation of RAD51C [21]. However, a considerable portion of breast tumors with HR defi-
ciency lack a known driver. Furthermore, less is known about whether the downstream effects
of germline variants, somatic variants, large deletions, and hypermethylation are similar to
each other or whether these effects are similar for different genes.
An underlying assumption of the BRCA-like concept is that the effects of HR deficiency are
similar across tumors, regardless of the genes that drive those deficiencies and despite consid-
erable variation in genetic backgrounds, environmental factors, and the presence of other
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driver mutations. Based on this assumption—and in a quest to identify additional genes that
contribute to being BRCA-like—we performed a systematic evaluation of multiomic and clini-
cal data from 1101 patients in The Cancer Genome Atlas (TCGA) [25]. In performing these
evaluations, we characterized each tumor using two types of molecular signature: 1) weights
that represent the tumor’s somatic-mutation profile and 2) the tumor’s mRNA expression pro-
file. To evaluate similarities among tumors based on these molecular profiles, we used a statis-
tical-resampling approach designed to quantify similarities among patient subgroups, even
when those subgroups are small, thus helping to account for rare events. We use “aberration”
as a general term to describe germline mutations, somatic mutations, copy-number deletions,
and hypermethylation events.
Methods
Data preparation and filtering
We obtained breast-cancer data from TCGA for 1101 patients in total. To determine germ-
line-mutation status, we downloaded raw sequencing data from CGHub [37] for normal
(blood) samples. We limited our analysis to whole-exome sequencing samples that had been
sequenced using Illumina Genome Analyzer or HiSeq equipment. Because the sequencing
data were stored in BAM format, we used Picard Tools (SamToFastq module, version 1.131,
http://broadinstitute.github.io/picard) to convert the files to FASTQ format. We used the Bur-
rows-Wheeler Alignment (BWA) tool (version 0.7.12) [38] to align the sequencing reads to
version 19 of the GENCODE reference genome (hg19 compatible) [39]. We used sambamba
(version 0.5.4) [40] to sort, index, mark duplicates, and flag statistics for the aligned BAM files.
In cases where multiple BAM files were available for a single patient, we used bamUtil (version
1.0.13, https://github.com/statgen/bamUtil) to merge the BAM files.
When searching for relevant germline variants, we examined 61 genes from the BROCA
Cancer Risk Panel (http://tests.labmed.washington.edu/BROCA) [41, 42]. We extracted geno-
mic data for these genes using bedtools (intersectBed module, version 2) [43].
We used Picard Tools (CalculateHsMetrics module) to calculate alignment metrics. For
exome-capture regions across all germline samples, the average sequencing coverage was 44.4.
The average percentage of target bases that achieved at least 30X coverage was 33.7%. The aver-
age percentage of target bases that achieved at least 100X coverage was 12.3%.
To call DNA variants, we used freebayes (version v0.9.21-18-gc15a283) [44] and Pindel
(https://github.com/genome/pindel). We used freebayes to identify single-nucleotide variants
(SNVs) and small insertions or deletions (indels); we used Pindel to identify medium-sized
insertions and deletions. Having called these variants, we used snpEff (version 4.1) [45] to
annotate the variants and GEMINI (version 0.16.3) [46] to query the variant data.
To expedite execution of the above steps, we used the GNU Parallel software [47]. The
scripts and code that we used to process the germline data can be found in an open-access
repository: https://bitbucket.org/srp33/tcga_germline.
Geneticists experienced in variant interpretation (BHS, TW, SG, MCK) evaluated each of
the germline variants for pathogenicity. Following accepted guidelines for variant classification
[42], variants were reviewed individually, followed by a group discussion. In evaluating each
variant, we first considered the likelihood of pathogenicity as reported in the University of
Washington, Department of Laboratory Medicine clinical-variant database. In addition, we
used functional annotations from SIFT [48], Polyphen2 [49], and GERP [50]. When evaluating
splice-site variants, we assessed pathogenicity based on whether the variants had been shown
experimentally to cause truncations. Additionally, we used NNsplice [51] and Rescue ESE [52]
to evaluate splicing variants. We also used maximum entropy modeling [53] and Human
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Splicing Finder [54], which aggregate data from other splice prediction tools. We classified as
benign any in-frame deletions that had been observed as naturally occurring transcripts. When
evaluating potential effects of a variant on protein function, we evaluated the extent to which a
given protein domain varies within the general population. This process for evaluating candidate
cancer-predisposing variants is used in clinical practice and has been demonstrated to maximize
actionable results and minimize the frequency of variants of unknown significance [42]. Personal
and family histories were unavailable for TCGA patients, so this information could not be
included in the evaluation process. The germline calls that we made for these patients were inde-
pendent of variant-classification calls used in prior studies of TCGA data [25, 55].
To assess loss of heterozygosity (LOH), we used data from Riaz et al. [56]. They had made
LOH calls for a large proportion of TCGA breast-cancer patients. Their process included an
evaluation of data from Affymetrix SNP 6.0 arrays, genotyping via Affymetrix’s birdseed algo-
rithm, and calculation of the log ratios and B-allele frequencies using PennCNV [57]. The
ASCAT algorithm [58] was used to determine allele-specific copy number and loss of hetero-
zygosity for each mutation.
We identified somatic SNVs and indels for each patient by examining variant calls that had
been made using Mutect [59]; these variants had been made available via the Genomic Data Com-
mons [60]. Somatic variants that 1) were synonymous 2) snpEff classified as having a “LOW” or
“MODIFIER” effect on protein sequence, 3) SIFT [48] and Polyphen2 [49] both suggested to be
benign [61], and 4) were observed at greater than 1% frequency across all populations in ExAC
[62] were excluded. For BRCA1 and BRCA2, we examined candidate variants based on a priori
observations of pathogenicity as reported in the University of Washington, Department of Labo-
ratory Medicine clinical-variant database [63]. Based on these criteria, we categorized each variant
as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign.
Then we examined ClinVar [64] for evidence that VUS or likely benign variants had been classi-
fied by others as pathogenic; however, none met this criterion. To err on the side of sensitivity, we
considered any BRCA1 and BRCA2 mutation to be “aberrant” if it fell into our pathogenic, likely
pathogenic, or VUS categories. The final classifications are shown in S1 Table.
Using the somatic-mutation data for each patient, we derived mutation-signature profiles
using the deconstructSigs (version 1.8.0) R package [65]. As input to this process, we used
somatic-variant calls that had not been filtered for pathogenicity, as a way to ensure adequate
representation of each signature. The output of this process was a vector for each tumor that
indicated a weight for each signature [19]. S1 and S2 Figs illustrate these weights for two
tumors that we analyzed.
We downloaded DNA methylation data via the Xena Functional Genomics Explorer [66].
These data were generated using the Illumina HumanMethylation27 and HumanMethyla-
tion450 BeadChip platforms. For the HumanMethylation27 arrays, we mapped probes to
genes using a file provided by the manufacturer (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GPL8490). For the HumanMethylation450 arrays, we mapped probes to genes using
an annotation file created by Price, et al. [67] (see http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GPL16304). Typically, multiple probes mapped to a given gene. Using probe-level
data from BRCA1, BRCA2, PTEN, and RAD51C, we performed a preliminary analysis to deter-
mine criteria for selecting and summarizing these probe-level values. We started with the
assumption that in most cases, the genes would be methylated at low levels. We also assumed
that probes nearest the transcription start site would be most informative. Upon plotting the
data (S3 Fig), we decided to limit our analysis to probes that mapped to the genome within 300
nucleotides of each gene’s transcription start site. In some cases, probes appeared to be faulty
because they showed considerably different methylation levels (“beta” values) than other
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probes in the region (S3 Fig). To mitigate the effects of these outliers, we calculated gene-level
methylation values as the median beta value across any remaining probes for that gene.
To identify tumors that exhibited relatively high beta values—and thus could be considered
to be hypermethylated—we used a univariate, outlier-detection algorithm, implemented in the
extremevalues R packages (version 2.3.2) [68]. This enabled us to look for extreme values
using one side of a specified distribution. This package supports five options for the distribu-
tion: normal (default), lognormal, exponential, pareto, and weibull. None of these distributions
was a consistently good fit for the methylation (beta) values, in part because the shape of the
data differed considerably across the genes (S4–S7 Figs). We used the exponential distribution
because it identified hypermethylated genes at rates that were largely consistent with prior
work [21]. We used the “getOutliersII” function with default parameter values.
We downloaded copy-number-variation data from the Xena Functional Genomics
Explorer [66]. These data had been generated using Affymetrix SNP 6.0 arrays; CNV calls had
been made using the GISTIC2 method [69]. The CNV calls had also been summarized to
gene-level values using integer-based discretization. We focused on tumors with a gene count
of “-2”, which indicates a homozygous deletion.
We used RNA-Sequencing data that had been aligned and summarized to gene-level values
using the original TCGA pipeline [25]. To facilitate biological and clinical interpretation, we
examined relationships between germline and somatic events and the Prosigna™ Breast Cancer
Prognostic Gene Signature (PAM50) subtypes [70]. Netanely, et al. had previously published
PAM50 subtypes for TCGA breast cancer samples; we reused this information in our study
[71]. We also sought to identify tumors with unusually low expression levels. To do this, we
used the getOutliersI function in the extremevalues package. We used the following non-
default parameter values: alpha = c(0.000001, 0.000001), distribution = "lognormal", FLim = c
(0.1, 0.9). RNA-Sequencing data have been shown to fit the log-normal distribution [72].
We parsed demographic, histopathological, and surgical variables for TCGA samples from
the repository prepared by Rahman, et al. [73]. We obtained drug-response data from the
TCGA legacy archive (https://portal.gdc.cancer.gov/legacy-archive) and standardized drug
names using synonyms from the National Cancer Institute Thesaurus [74].
Quantitative analysis and visualization
To prepare, analyze, and visualize the data, we wrote computer scripts in the R programming
language [75]. In writing these scripts, we used the following packages: readr [76], dplyr [77],
ggplot2 [78], tidyr [79], reshape2 [80], ggrepel [81], cowplot [82], data.table [83], UpSetR [84],
BSgenome.Hsapiens.UCSC.hg38 [85, 86], and Rtsne [87].
To reduce data dimensionality, we applied multidimensional scaling (MDS) [88] to the
somatic-mutation signatures and gene-expression profiles. This reduced the data to two
dimensions. To quantify homogeneity within a group of tumors that harbored a particular
aberration, we calculated the pairwise Euclidean distance between each patient pair in the
group and then calculated the median pairwise distance, based on the two-dimensional values
[89]. As an additional measure of homogeneity, we used logistic regression to predict BRCA
mutation status using the dimensionally reduced coordinates. In evaluating this approach, we
used two-fold cross validation and configured the model to weight the minority class in inverse
proportion to the frequency of the minority class.
When comparing two given groups, we used a similar resampling approach but instead cal-
culated the median distance between each pair of individuals in either group. To determine
whether the similarity within or between groups was statistically significant, we used a permu-
tation approach. We randomized the patient identifiers, calculated the median pairwise
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distance within (or between) groups, and repeated those steps 100,000 times. This process
resulted in an empirical null distribution against which we compared the actual median dis-
tance. We then derived empirical p-values by calculating the proportion of randomized
median distances that were larger than the actual median distance. We adjusted the empirical
p-values for multiple testing using Holm’s method [90]; we applied this correction to the p-val-
ues across all aberration types.
For visualization, we plotted the MDS values as Cartesian coordinates; we also used Barnes-
Hut t-distributed Stochastic Neighbor Embedding (t-SNE) [91, 92] as an alternative method
for visualizing the data.
We created a series of R scripts that execute all steps of our analysis and that generate the
figures in this paper; these scripts are available at https://osf.io/9jhr2.
Ethics statement
Brigham Young University’s Institutional Review Board approved this study under exemption
status. This study uses data collected from public repositories, other than the germline-variant
data, which are restricted by TCGA data-access policies. We played no part in patient recruiting
or in obtaining patient consent. We have adhered to guidelines from TCGA on handling data.
Results
We used clinical and molecular data from 1101 TCGA breast-cancer patients to evaluate the
downstream effects of BRCA1 and BRCA2 germline mutations in tumors. We evaluated two
types of downstream effects: 1) signatures that reflect a tumor’s overall somatic-mutation pro-
file in a trinucleotide context and 2) tumor gene-expression levels. We used somatic-mutation
signatures because they reflect the genomic effects of HR defects and have been associated
with BRCA1/BRCA2 mutation status [18, 19]. We used gene-expression data because they are
used to classify breast tumors into subtypes [93, 94] and often reflect genomic variation [61,
95, 96]. We assessed whether either of these types of profiles was more homogeneous in
BRCA1/BRCA2 germline carriers than in randomly selected patients. In addition, we evaluated
potential criteria for classifying tumors into the BRCA-like category. These criteria included
somatic mutations, homozygous deletions, and DNA hypermethylation of BRCA1 and
BRCA2. Similarly, we assessed whether these different types of aberrations have downstream
effects similar to BRCA1/BRCA2 for 59 other cancer-predisposition genes.
Somatic-mutation signatures and gene-expression profiles across all
breast-cancer patients
First, we identified the primary somatic-mutation signature associated with each TCGA
breast-cancer patient. Approximately 91% of the patients were associated with somatic-muta-
tion signature “1A” (n = 670), “1B” (n = 48), “2” (n = 98), or “3” (n = 130). The remaining
patients were assigned to 12 other signatures (S8 Fig). Second, we identified the primary
PAM50 gene-expression subtype associated with each patient. The Luminal A and Luminal B
subtypes were most common, but each subtype was represented by at least 37 tumors (S9 Fig).
Fig 1. Two-dimensional representation of somatic-mutation signatures using multidimensional scaling. We summarized each tumor based on their somatic-
mutation signatures, which represent overall mutational patterns in a trinucleotide context. We used multidimensional scaling (MDS) to reduce the data to two
dimensions. Each point represents a single tumor, overlaid with colors that represent the tumor’s primary somatic-mutation signature. Mutational Signature 1A (A)
was the most prevalent; these tumors were widely dispersed across the signature landscape. Signatures 1B (B), 2 (C), and 3 (D) were relatively small and formed
cohesive clusters. The remaining 23 clusters were rare individually and were dispersed broadly.
https://doi.org/10.1371/journal.pone.0239197.g001
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Fig 2. Two-dimensional representation of gene-expression levels using multidimensional scaling. We used multidimensional scaling (MDS) to reduce the
gene-expression profiles to two dimensions. Each point represents a single tumor, overlaid with colors that represent the tumor’s primary PAM50 subtype.
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Although it is useful to evaluate the primary somatic-mutation signature or PAM50 subtype
associated with each tumor, tumors are aggregates of multiple signatures and subtypes. To
account for this diversity, we characterized the tumors based on 1) all 27 somatic-mutation sig-
natures or 2) expression levels for all available genes. To enable easier interpretation of these
profiles, we reduced dimensionality of the data using the MDS and t-SNE techniques (see
Methods). Generally, tumors with the same primary somatic-mutation signature or PAM50
subtype clustered together in these visualizations (Figs 1 and 2; S10 and S11 Figs); however, in
some cases, this did not happen. For example, the dimensionally reduced gene-expression pro-
files for Basal-like tumors formed a cluster that was mostly separate from the other tumors; but
some Basal-like tumors were modestly distant from this cluster, and some Normal-like tumors
clustered closely with the Basal-like tumors (Fig 2; S11 Fig). Tumors assigned to somatic-muta-
tion “Signature 3” formed a cohesive cluster (Fig 1; S10 Fig), but some “Signature 3” tumors
were modestly distant from this cluster. These observations highlight the importance of evalu-
ating molecular profiles as a whole, not just using the primary category for each tumor.
Aberrations in BRCA1 and BRCA2
Of 993 breast-cancer patients with available germline data, 22 harbored a pathogenic SNV or
indel in BRCA1; 22 harbored a BRCA2 variant (Fig 3A). We were able to identify loss of het-
erozygosity (LOH) for all but 3 BRCA1 carriers and 7 BRCA2 carriers (S12 and S13 Figs). A
somatic mutation, homozygous deletion, or hypermethylation event occurred in BRCA1 or
BRCA2 for 80 patients (Fig 3B–3D). Most of these events were mutually exclusive with each
other and with germline variants (S14 Fig).
BRCA1 carriers fell into the Basal (n = 17); Her2-enriched (n = 1), Luminal A (n = 2), and
Luminal B (n = 1) gene-expression subtypes (S15 Fig) [22, 93, 94]. We were unable to assign a
gene-expression subtype to one BRCA1 carrier due to missing data. Most BRCA2 carriers fell
into the Luminal A subtype (n = 13); the remaining individuals were dispersed across the
other subtypes. As demonstrated previously [19], the primary somatic-mutation signature for
most BRCA1 and BRCA2 carriers was “Signature 3”; however, other signatures (especially
“1A”) were also common (S16 Fig). S17 Fig shows the overlap between these two types of
molecular profile.
Homogeneity of somatic mutation signature and expression profiles of
germline BRCA1/2 carriers
The somatic-mutation signatures of BRCA1 germline carriers were more homogeneous than
expected by chance (p = 0.00056; S18A, S19A and S20A Figs), as were those from BRCA2 carri-
ers (p = 0.0003; S18B, S19B and S20B Figs). As an additional measure of homogeneity, we used
logistic regression to predict BRCA aberration status based on the dimensionally reduced data.
Using somatic-mutation signatures, we could predict the presence of BRCA1 germline muta-
tions with a sensitivity of 0.72 and a specificity of 0.82. Additional classification results are
shown in S2 Table.
None of the three BRCA1 carriers who lacked LOH events clustered closely with the
remaining BRCA1 tumors (S18A and S19A Figs). Of the 7 BRCA2 tumors without detected
LOH events, 3 clustered closely with the remaining BRCA2 tumors, while 4 did not (S18B and
Generally, the PAM50 subtypes clustered cohesively, but there were exceptions. For example, some Basal-like tumors (A) exhbited expression patterns that
differed considerably from the remaining Basal-like tumors. The normal-like tumors (E) showed the most variability in expression. This graph represents
patients for whom we could identify a PAM50 subtype.
https://doi.org/10.1371/journal.pone.0239197.g002
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Fig 3. Molecular aberrations in BRCA1 and BRCA2 across all breast-cancer patients. A) Germline mutations, B) Somatic mutations, C) Copy-number
variations, D) DNA methylation levels. SNV = single nucleotide variation.
https://doi.org/10.1371/journal.pone.0239197.g003
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S19B Figs). It has been shown previously that germline BRCA1/BRCA2 mutations leave a rec-
ognizable imprint on a tumor’s mutational landscape [19]. This effect may be more consistent
when a LOH event has occurred as a second “hit” within the same gene [97], but this was diffi-
cult to confirm with the available sample sizes.
Under the assumption that BRCA1/BRCA2 germline variants induce recognizable effects
on tumor transcription, we assessed whether tumors from BRCA1/BRCA2 carriers have homo-
geneous gene-expression profiles. As expected based on the tumors’ primary PAM50 classifi-
cation, 17 of 21 BRCA1 carriers (for whom we had gene-expression data) overlapped closely
with the Basal-like subtype (S15 Fig). As a whole, the expression profiles for this group were
more homogeneous than expected by chance (p = 0.0318; S21A, S22A and S23A Figs). How-
ever, expression values for BRCA2 carriers were not significantly homogeneous (p = 1.0; S23B
Fig). Tumors from these individuals were dispersed across the gene-expression landscape
(S21B and S22B Figs).
Similarities among individuals with BRCA1/BRCA2 aberrations
Next we evaluated similarities between BRCA1 and BRCA2 germline carriers. Somatic-muta-
tion signatures for BRCA1 and BRCA2 carriers were highly similar to each other (p = 0.00014;
S18A, S18B, S19A, S19B and S24A Figs). However, this pattern did not hold for gene-expres-
sion profiles. Although some BRCA2 carriers fell into the Basal-like gene-expression subtype,
overall profiles for these patients were dissimilar to those from BRCA1 carriers (p = 1.0; S21A,
S21B, S22A, S22B and S25A Figs).
Whether for somatic-mutation signatures or gene-expression profiles, tumors with BRCA1
hypermethylation were relatively homogeneous and highly similar to tumors from BRCA1
germline carriers (Table 1; S18G, S19G, S20G, S21G, S22G and S23G Figs). For gene-expres-
sion data, no other aberration type showed significant similarity to BRCA1 germline muta-
tions. Somatic-mutation signatures from tumors with BRCA1 somatic mutations were
significantly similar to those from BRCA1 germline mutations (Table 1). Only 2 tumors had
BRCA2 hypermethylation, but the mutational signatures for these samples were significantly
similar to tumors from BRCA2 germline carriers (p = 0.00054; S19H Fig). Likewise, tumors
with a BRCA2 somatic mutation or homozygous deletion had mutational signatures that were
similar to germline BRCA2 carriers (Table 1; S18D, S18F, S19D and S19F Figs). Aberrations in
BRCA1 and BRCA2 appear to induce similar effects on somatic-mutation signatures—but not
necessarily gene expression—whether those disruptions originate in the germline or via
somatic events.
Table 1. Results of similarity comparisons among BRCA aberration groups. We compared somatic-mutation signatures or gene-expression profiles between groups of
patients who harbored aberrations in BRCA1 or BRCA2. We evaluated whether patients in one group (e.g., those who harbored a BRCA1 germline mutation) were more
similar to patients in a second group (e.g., those with BRCA2 germline mutation) than random patient subsets of the same sizes. The numbers in this table represent empir-
ical p-values from our resampling approach. In cases where an individual harbored an aberration in both comparison groups, we excluded that patient from the compari-
son. We used Holm’s method to correct for testing multiple hypotheses.
Aberration Type 1 Aberration Type 2 Gene Expression Mutational Signatures
BRCA1 germline mutation (n = 22) BRCA2 germline mutation (n = 22) 1.0 1.4e-04
BRCA1 germline mutation (n = 22) BRCA1 somatic mutation (n = 14) 1.0 1.4e-04
BRCA1 germline mutation (n = 22) BRCA1 homozygous deletion (n = 8) 1.0 0.30
BRCA1 germline mutation (n = 22) BRCA1 hypermethylation (n = 36) 0.013 1.4e-04
BRCA2 germline mutation (n = 22) BRCA2 somatic mutation (n = 12) 1.0 1.4e-04
BRCA2 germline mutation (n = 22) BRCA2 homozygous deletion (n = 19) 1.0 1.4e-04
BRCA2 germline mutation (n = 22) BRCA2 hypermethylation (n = 2) 1.0 5.4e-04
https://doi.org/10.1371/journal.pone.0239197.t001
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Evaluation of aberrations in other cancer-predisposing genes and clinical
factors
Next we aggregated all patients who had any type of BRCA1 or BRCA2 aberration into a
“BRCA-like reference group.” As a whole, mutational signatures for this group were more
homogeneous than expected by chance (p = 0.00001; S26 Fig). We used this reference group to
evaluate 59 other cancer-predisposition genes that might be associated with being BRCA-like.
For the remaining evaluations, we used somatic-mutation signatures only.
We evaluated whether molecular aberrations in the cancer-predisposition genes resulted in
mutational signatures that were similar to our BRCA-like reference group. We found patho-
genic and likely pathogenic germline mutations in 13 genes (ATM, BARD1, BRCA1, BRCA2,
BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD51B, RAD51C, SLX4, TP53, XRCC2). The
most frequently mutated were CHEK2, ATM, and NBN (Fig 4; S27 and S28 Figs). We found
potentially pathogenic somatic mutations in 55 genes, most frequently in TP53, PIK3CA,
CDH1, and PTEN (Fig 5; S29 and S30 Figs). Homozygous deletions occurred most frequently
in PTEN, CDKN2A, RB1, and CDH1 (Fig 6; S31 and S32 Figs). Hypermethylation occurred in
22 genes, most commonly GALNT12, PTCH1, CDKN2A, and RAD51C (Fig 7, S33 and S34
Figs). Using our resampling approach, we compared each aberration type in each gene against
the BRCA-like reference group. In cases where an aberration overlapped between the reference
and comparison groups, we excluded individuals who harbored both aberrations. For 11 genes
(ATR, BARD1, CDKN2A, CTNNA1, PALB2, PALLD, PRSS1, RAD51B, SDHC, SMARCA4,
VHL), at least one type of aberration attained statistical significance after multiple-testing cor-
rection (Table 2). A total of 8 aberrations occurred in BARD1: a germline mutation, 2 somatic
mutations, and 5 homozygous deletions; as a group, these tumors were statistically similar to
the BRCA-like reference group (p = 0.0018). ATR was mutated in 15 tumors and hypermethy-
lated in 1 tumor; together, these tumors were statistically similar to the BRCA-like reference
group (p = 0.0035). Tumors with an aberration in PRSS1 were also statistically similar to the
BRCA-like reference group (p = 0.0069), but we only observed 2 aberrations in this gene.
Other genes showed high similarity to the BRCA-like reference group for one type of aberra-
tion only; these included homozygous deletions in CDKN2A (n = 47; p = 0.00001), homozy-
gous deletions in CTNNA1 (n = 6; p = 0.00004), germline mutations in PALB2 (n = 3;
p = 0.00001), and homozygous deletions in PALLD (n = 9; p = 0.00001).
Lastly, we evaluated whether the following data types were correlated with being BRCA-
like: 1) unusually low mRNA expression in a given gene, 2) demographic, histopathological,
and surgical observations, and 3) patient drug responses. First, we calculated the median
Euclidean distance—based on somatic-mutation signatures—between each patient and the
BRCA-like reference group. Then we used a two-sided Pearson correlation test to assess the
relationship between these median distances and each candidate variable. In determining
whether a tumor exhibited unusually low mRNA expression for a given gene, we used an out-
lier-detection technique (see Methods). Unusually low expression of BRCA1 (rho = 0.22,
p = 0.0024) and RAD51C (rho = 0.20, p = 0.016) showed the strongest positive correlation with
the reference group, whereas CDH1 (rho = -0.19, p = 0.023), PIK3CA (rho = -0.19, p = 0.025)
and BARD1 (rho = -0.19, p = 0.028) showed the strongest negative correlation (S35 and S36
Fig 4. Non-BRCA germline mutations on the somatic-mutation signature landscape using multidimensional scaling. Using the same two-dimensional
representation of mutational signatures shown in Fig 1, this plot indicates which patients had germline mutations in non-BRCA cancer-predisposition genes.
Diamond shapes indicate patients for whom no loss-of-heterozygosity was observed.
https://doi.org/10.1371/journal.pone.0239197.g004
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Figs). Triple-negative status and infiltrating ductal carcinoma histology were the most posi-
tively correlated clinical variables (S37 Fig). No chemotherapy treatment was significantly
associated with being BRCA-like, though availability was limited for the drug data (n = 211;
S38 Fig). Relationships among low mRNA expression and these factors are likely interwoven.
For example, CDH1 expression has been associated with molecular subtypes such as triple-
negative status [98]. Larger studies will be necessary to disentangle these effects.
Discussion
The concept of being BRCA-like has traditionally focused on tumors aberrations, under the
hypothesis that their effects are similar to those of germline BRCA1 and BRCA2 mutations
[31]. We evaluated this hypothesis for somatic mutations, homozygous deletions, and hyper-
methylation events in BRCA1 and BRCA2. Corroborating prior evidence [21, 33], we found
that tumors with these aberration types had somatic-mutation signatures that were similar to
those of germline carriers. Using this group as a reference, we evaluated each aberration type,
as well as germline mutations, in 59 other cancer-predisposition genes in search of additional
criteria that might be indicators of being BRCA-like. This search identified previously known
associations with being BRCA-like, including germline mutations in PALB2 [21] and somatic
mutations in ATR [32]. However, for a gene to be considered a strong candidate for inclusion
in the BRCA-like definition, we required evidence of similarity across all available molecular
data types. BARD1 and ATR met these criteria. Both genes interact directly with BRCA1 to
help repair double-stranded breaks and control G1/S cell-cycle arrest [99]. Experimental evi-
dence lends support to the hypothesis that inactivation of these genes has relevance to being
BRCA-like. For example, in mice, inactivation of the Bard1 protein induces mammary tumors
that are indistinguishable from tumors that result from Brca1 knock-out [100]. In triple-nega-
tive breast cancers, ATR inhibitors are highly efficient in patient-derived xenografts that have
a BRCA1 mutation or that exhibit the BRCA-like phenocopy when combined with irinotecan,
a clinically approved topoisomerase 1 inhibitor that causes double-stranded breaks [101].
Interestingly, other genes known to play a role in DNA damage repair [102]–including
ATM, CHEK2, and RAD51C—did not attain statistical significance for any aberration type.
The family-wise method we used to correct for multiple testing is generally conservative [90].
Accordingly, our results likely erred on the side of specificity rather than sensitivity for esti-
mating whether a given gene should be considered a candidate for the BRCA-like category.
This may explain why RAD51C hypermethylation, for example, did not reach statistical signifi-
cance in our analysis, even though it has been highlighted in other studies [21, 33].
When using gene-expression profiles to characterize being BRCA-like, we observed a clear
relationship between BRCA1 aberrations and the “Basal-like” gene-expression subtype, con-
firming prior findings [22–25]. Our findings extended to triple-negative tumors, again con-
firming prior evidence [26, 27]. Hedenfalk, et al. demonstrated that breast tumors from
BRCA1 and BRCA2 carriers exhibit gene-expression patterns that are distinct from each other
[103]; our analysis confirmed these findings. Rice, et al. identified correlations between tran-
scriptional inactivation of BRCA1 and either germline mutations or hypermethylation of the
same gene [104]. Considering potential effects across the transcriptome, our analysis provided
additional evidence that gene-expression profiles from tumors of BRCA1 germline carriers are
highly similar to tumors with BRCA1 hypermethylation. These findings did not extend to
Fig 5. Non-BRCA somatic mutations on the somatic-mutation signature landscape using multidimensional scaling. Using the same two-dimensional
representation of mutational signatures shown in Fig 1, this plot indicates which patients had somatic mutations in non-BRCA cancer-predisposition genes.
Diamond shapes indicate patients for whom no loss-of-heterozygosity was observed.
https://doi.org/10.1371/journal.pone.0239197.g005
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BRCA2. Moelans, et al. found that BRCA2 hypermethylation occurs frequently in ductal carci-
noma in situ lesions and in adjacent invasive ductal cancer cells [105]; however, we identified
only 2 samples that were hypermethylated for this gene.
Although gene-expression data may be less useful than somatic-mutation signatures for
characterizing the effects of HR defects, they may hold promise as predictive biomarkers for
specific patient subgroups. For example, Tutt, et al. observed that triple-negative hormone sta-
tus was a reliable biomarker of objective treatment responses to carboplatin [106]. Severson,
et al. treated HER2-negative patients with a combination of veliparib, a PARP inhibitor, and
carboplatin, a platinum agent, in a neoadjuvant setting. In addition, they derived a gene-
expression signature that characterized “BRCA1ness” and found that this signature was associ-
ated with response to this combination therapy [28]. In ovarian tumors, Konstantinopoulos,
et al. derived a gene-expression signature that distinguished “BRCA-like” from “non–BRCA-
like” samples and used this signature to accurately predict sensitivity or resistance to a plati-
num agent and a PARP inhibitor in patient-derived specimens [29]. Finally, Mulligan, et al.
developed a 44-gene assay and showed that differences in expression of these genes between
BRCA1/BRCA2 mutant and sporadic tumors were predictive of response to DNA-damaging
agents [107]. We attempted to replicate these findings with TCGA data, but sample sizes were
too small on a per-drug basis.
Davies, et al. aimed to develop a BRCA-like biomarker using somatic-mutation signa-
tures [33]. Using a lasso logistic-regression model, they were able to identify aberrant
BRCA1/BRCA2 tumors with near perfect accuracy and then extended their approach to
identify tumors with an apparent functional HR deficiency that lacked known aberrations
in these genes. In contrast, we focused on identifying candidate BRCA-like genes, rather
than to develop a predictive biomarker for being BRCA-like itself (or for treatment
responses). By identifying such genes, we aimed to provide insights into possible mecha-
nisms of being BRCA-like. Such insights might indirectly be useful for predicting sensitivity
to PARP inhibitors or platinum agents, although this connection is still tenuous [32, 108].
Polak, et al. used an alternative methodology to ours, associating somatic-mutation signa-
tures with genomic aberrations in TCGA breast-cancer samples; they identified some of the
same relationships that we identified [21]. However, our analysis extended to additional
genes and factors, including extremely low-expressing genes and clinical variables. In addi-
tion, we explicitly compared the effects on somatic-mutation signatures of BRCA1 versus
BRCA2 aberrations.
Different types of aberration may result in different downstream effects; however, these dif-
ferences may result from technical challenges in identifying and filtering variants. Determin-
ing which genmic aberrations are pathogenic remains a challenging task [109], so it is likely
that more- or less-stringent filtering of candidate aberrations would lead to more accurate
results. In addition, we could not always determine whether mono- or bi-allelic inactivation of
a given gene had occurred in a given tumor; mono-allelic inactivation may be insufficient to
impair HR function [56].
Finally, we note methodological issues. To enable easier visualization, we reduced the
molecular signatures to two dimensions. We also used the dimensionally reduced data as
input to our statistical resampling approach. Accordingly, even though the number of original
input variables was much larger for the gene-expression data, this approach enabled us to
Fig 6. Non-BRCA homozygous deletions on the somatic-mutation signature landscape using multidimensional scaling. Using the same two-dimensional
representation of mutational signatures shown in Fig 1, this plot indicates which patients had homozygous deletions in non-BRCA cancer-predisposition genes.
Diamond shapes indicate patients for whom no loss-of-heterozygosity was observed.
https://doi.org/10.1371/journal.pone.0239197.g006
PLOS ONE Effects of germline and somatic events in candidate BRCAness genes on breast-tumor signatures
PLOS ONE | https://doi.org/10.1371/journal.pone.0239197 September 30, 2020 17 / 32
PLOS ONE Effects of germline and somatic events in candidate BRCAness genes on breast-tumor signatures
PLOS ONE | https://doi.org/10.1371/journal.pone.0239197 September 30, 2020 18 / 32
perform a more consistent comparison between the two data types. However, reducing the
data to this extent likely failed to capture much of the biological signal in the data for either
data type. Further refining this approach may help to strike a better balance between data
interpretability and adequate data representation [110].
Fig 7. Non-BRCA hypermethylation events on the somatic-mutation signature landscape using multidimensional scaling. Using the same two-dimensional
representation of mutational signatures shown in Fig 1, this plot indicates which patients had hypermethylation events in non-BRCA cancer-predisposition genes.
Diamond shapes indicate patients for whom no loss-of-heterozygosity was observed.
https://doi.org/10.1371/journal.pone.0239197.g007
Table 2. Summary of comparisons between the BRCA-like reference group and groups of patients who harbored a specific type of aberration in a candidate BRCA-
like gene. We evaluated whether somatic-mutation signatures from patients who harbored a given type of aberration (e.g., BARD1 germline mutation) were more similar
to the BRCA-like reference group than expected by random chance. The numbers in this table represent empirical p-values from our resampling approach. In cases where
no patient had a given type of aberration in a given gene, we list “N/A”. The “Any” group represents individuals who harbored any type of aberration in a given gene. We
used Holm’s method to correct for testing multiple hypotheses.
Gene Germline mutation Somatic mutation Homozygous deletion Hypermethylation Any
AKT1 N/A 1.0 (n = 21) 1.0 (n = 3) 0.13 (n = 1) 1.0 (n = 25)
APC N/A 1.0 (n = 19) 1.0 (n = 7) N/A 1.0 (n = 26)
ATM 1.0 (n = 11) 1.0 (n = 18) 1.0 (n = 16) N/A 1.0 (n = 46)
ATR N/A 0.0018 (n = 15) N/A 1.0 (n = 1) 0.0035 (n = 16)
AXIN2 N/A 1.0 (n = 6) N/A N/A 1.0 (n = 7)
BAP1 N/A 1.0 (n = 6) 1.0 (n = 7) N/A 1.0 (n = 13)
BARD1 0.0018 (n = 1) 0.0018 (n = 2) 0.054 (n = 5) N/A 0.0018 (n = 8)
BMPR1A N/A 1.0 (n = 2) 1.0 (n = 8) 1.0 (n = 1) 1.0 (n = 11)
BRIP1 1.0 (n = 2) 1.0 (n = 8) N/A N/A 1.0 (n = 11)
CDH1 1.0 (n = 2) 1.0 (n = 135) 1.0 (n = 22) N/A 1.0 (n = 159)
CDK4 N/A 1.0 (n = 2) N/A N/A 1.0 (n = 3)
CDKN2A N/A N/A 0.0018 (n = 47) 1.0 (n = 53) 0.57 (n = 100)
CHEK1 N/A 1.0 (n = 4) 1.0 (n = 16) N/A 1.0 (n = 20)
CHEK2 1.0 (n = 25) 1.0 (n = 6) 1.0 (n = 1) N/A 1.0 (n = 32)
CTNNA1 N/A 1.0 (n = 8) 0.0069 (n = 6) N/A 1.0 (n = 14)
FAM175A N/A 0.085 (n = 2) 1.0 (n = 3) N/A 0.055 (n = 5)
FH N/A 1.0 (n = 3) 1.0 (n = 1) N/A 1.0 (n = 4)
FLCN N/A 1.0 (n = 2) 1.0 (n = 8) N/A 1.0 (n = 10)
GALNT12 N/A 1.0 (n = 7) 1.0 (n = 3) 1.0 (n = 79) 1.0 (n = 89)
GEN1 N/A 1.0 (n = 2) 1.0 (n = 3) N/A 1.0 (n = 5)
GREM1 N/A 1.0 (n = 2) 1.0 (n = 15) N/A 1.0 (n = 17)
HOXB13 N/A 1.0 (n = 3) N/A N/A 1.0 (n = 4)
MEN1 N/A 1.0 (n = 9) 1.0 (n = 3) N/A 1.0 (n = 13)
MLH1 N/A 1.0 (n = 13) 1.0 (n = 4) 1.0 (n = 19) 1.0 (n = 36)
MRE11A N/A 1.0 (n = 2) 1.0 (n = 8) 1.0 (n = 2) 1.0 (n = 12)
MSH2 N/A 1.0 (n = 4) N/A N/A 1.0 (n = 5)
MSH6 N/A 1.0 (n = 7) N/A N/A 1.0 (n = 8)
MUTYH N/A 1.0 (n = 3) N/A N/A 1.0 (n = 3)
NBN 1.0 (n = 5) 1.0 (n = 5) N/A N/A 1.0 (n = 10)
NF1 N/A 1.0 (n = 40) 1.0 (n = 7) N/A 1.0 (n = 47)
NTHL1 N/A 1.0 (n = 1) N/A N/A 1.0 (n = 1)
PALB2 0.0018 (n = 3) 1.0 (n = 5) N/A N/A 0.12 (n = 8)
PALLD N/A 1.0 (n = 6) 0.0018 (n = 9) 1.0 (n = 7) 1.0 (n = 22)
PIK3CA N/A 1.0 (n = 190) N/A N/A 1.0 (n = 191)
PMS2 N/A 1.0 (n = 5) 0.49 (n = 1) N/A 1.0 (n = 6)
(Continued)
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Supporting information
S1 Fig. Somatic-mutation signature weights for one Signature 3 tumor. This tumor had a
large proportion of C>T mutations, which are representative of Signature 3.
(PDF)
S2 Fig. Somatic-mutation signature weights for a second Signature 3 tumor. This tumor
had a large proportion of C>T mutations, which are representative of Signature 3.
(PDF)
S3 Fig. Probe-level summarization of DNA methylation probes. We extracted probe-level
methylation (beta) values for all available breast-cancer samples in TCGA and plotted them
relative to the transcription start site of each gene. These graphs illustrate beta values for four
genes (BRCA1, BRCA2, PTEN, and RAD51C) and two microarray platforms (Illumina
HumanMethylation 27K and 450K). Values in parenthesis indicate distance from the tran-
scription start site (TSS). TSS distances marked as “NA” were unavailable. The 27K arrays
have fewer probes per gene. In general, probes near the TSS exhibited relatively low methyla-
tion levels for these genes, whereas probes further from the TSS were more highly methylated.
These observations are consistent with the assumption that most genes would be “on” by
default. Some exceptions to this pattern are apparent (for example, cg13782816 on panel C);
these exceptions may be caused by mismapped probes, cross hybridization, or misannotations.
We calculated gene-level values as the median across all probes that were within 300
Table 2. (Continued)
Gene Germline mutation Somatic mutation Homozygous deletion Hypermethylation Any
POLD1 N/A 1.0 (n = 3) 1.0 (n = 2) N/A 1.0 (n = 6)
POLE N/A 0.091 (n = 16) 1.0 (n = 4) N/A 0.33 (n = 20)
POT1 N/A 1.0 (n = 5) 1.0 (n = 1) N/A 1.0 (n = 6)
PRKAR1A N/A 1.0 (n = 7) N/A N/A 1.0 (n = 7)
PRSS1 N/A 1.0 (n = 1) 0.0018 (n = 1) N/A 0.0069 (n = 2)
PTCH1 N/A 1.0 (n = 16) 1.0 (n = 3) 1.0 (n = 69) 1.0 (n = 88)
PTEN 1.0 (n = 1) 1.0 (n = 51) 0.30 (n = 56) 1.0 (n = 2) 1.0 (n = 110)
RAD51B 0.0018 (n = 3) 1.0 (n = 3) 1.0 (n = 9) N/A 0.64 (n = 15)
RAD51C 0.61 (n = 1) 1.0 (n = 3) 1.0 (n = 2) 0.098 (n = 35) 0.61 (n = 41)
RAD51D N/A 1.0 (n = 3) 1.0 (n = 4) N/A 1.0 (n = 7)
RB1 N/A 1.0 (n = 19) 1.0 (n = 45) 1.0 (n = 2) 1.0 (n = 66)
RET N/A 1.0 (n = 5) 1.0 (n = 2) 1.0 (n = 10) 1.0 (n = 17)
RINT1 N/A 1.0 (n = 5) N/A N/A 1.0 (n = 6)
RPS20 N/A N/A N/A 1.0 (n = 2) 1.0 (n = 3)
SDHB N/A 1.0 (n = 1) 1.0 (n = 7) N/A 1.0 (n = 9)
SDHC N/A N/A N/A 0.03 (n = 1) 0.032 (n = 1)
SDHD N/A N/A 1.0 (n = 16) N/A 1.0 (n = 16)
SLX4 1.0 (n = 1) 1.0 (n = 10) N/A N/A 1.0 (n = 12)
SMAD4 N/A 1.0 (n = 12) 1.0 (n = 14) N/A 1.0 (n = 26)
SMARCA4 N/A 1.0 (n = 7) 0.0018 (n = 2) N/A 1.0 (n = 9)
STK11 N/A 0.13 (n = 2) 1.0 (n = 12) N/A 1.0 (n = 14)
TP53 1.0 (n = 2) 1.0 (n = 302) 1.0 (n = 15) N/A 1.0 (n = 319)
VHL N/A 0.0018 (n = 1) 1.0 (n = 1) N/A 1.0 (n = 2)
XRCC2 1.0 (n = 4) 1.0 (n = 3) 1.0 (n = 4) N/A 1.0 (n = 11)
https://doi.org/10.1371/journal.pone.0239197.t002
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nucleotides of the TSS.
(PDF)
S4 Fig. Fit of outlier-detection model to DNA methylation data for BRCA1. We used an
outlier-detection methodology to estimate which tumors were hypermethylated for a given
gene. This scatter plot illustrates the model fit for BRCA1. Asterisks represent tumors consid-
ered to be outliers.
(PDF)
S5 Fig. Fit of outlier-detection model to DNA methylation data for BRCA2. We used an
outlier-detection methodology to estimate which tumors were hypermethylated for a given
gene. This scatter plot illustrates the model fit for BRCA2. Asterisks represent tumors consid-
ered to be outliers.
(PDF)
S6 Fig. Fit of outlier-detection model to DNA methylation data for PTEN. We used an out-
lier-detection methodology to estimate which tumors were hypermethylated for a given gene.
This scatter plot illustrates the model fit for PTEN. Asterisks represent tumors considered to
be outliers.
(PDF)
S7 Fig. Fit of outlier-detection model to DNA methylation data for RAD51C. We used an
outlier-detection methodology to estimate which tumors were hypermethylated for a given
gene. This scatter plot illustrates the model fit for RAD51C. Asterisks represent tumors consid-
ered to be outliers.
(PDF)
S8 Fig. Primary somatic-mutation signature across all breast-cancer patients. Each TCGA
breast-cancer patient was assigned to a primary somatic-mutation signature based on exome-
wide mutational patterns. This plot illustrates the frequency of each somatic-mutation signa-
ture across all the patients.
(PDF)
S9 Fig. Primary PAM50 subtypes across all breast-cancer patients. Each TCGA breast-can-
cer patient was assigned to a primary PAM50 subtype based on tumor gene-expression levels.
This plot illustrates the frequency of each PAM50 subtype across all the patients.
(PDF)
S10 Fig. Two-dimensional representation of somatic-mutation signatures using the t-SNE
method. We summarized each tumor based on their somatic-mutation signatures, which rep-
resent overall mutational patterns in a trinucleotide context. We used the t-distributed Sto-
chastic Neighbor Embedding (t-SNE) method to reduce the data to two dimensions. Each
point represents a single tumor, overlaid with colors that represent the tumor’s primary
somatic-mutation signature. Mutational Signature 1A (A) was the most prevalent; these
tumors were widely dispersed across the signature landscape. Signatures 1B (B), 2 (C), and 3
(D) were relatively small and formed cohesive clusters. The remaining 23 clusters were rare
individually and were dispersed broadly.
(PDF)
S11 Fig. Two-dimensional representation of gene-expression levels using the t-SNE
method. We used the t-distributed Stochastic Neighbor Embedding (t-SNE) method to reduce
the gene-expression profiles to two dimensions. Each point represents a single tumor, overlaid
with colors that represent the tumor’s primary PAM50 subtype. Generally, the PAM50
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subtypes clustered cohesively, but there were exceptions. For example, some Basal-like tumors
(A) exhbited expression patterns that differed considerably from the remaining Basal-like
tumors. The normal-like tumors (E) showed the most variability in expression. This graph rep-
resents patients for whom we could identify a PAM50 subtype.
(PDF)
S12 Fig. Intersection between germline-mutation status and loss of heterozygosity for
BRCA1. A total of 22 patients carried a germline mutation in BRCA1. We detected loss-of-het-
erozygosity events in tumors for all but 3 of these patients. Data are only shown for patients for
whom we had both types of data.
(PDF)
S13 Fig. Intersection between germline-mutation status and loss of heterozygosity for
BRCA2. A total of 22 patients carried a germline mutation in BRCA2. We detected loss-of-het-
erozygosity events in tumors from all but 7 of these patients. Data are only shown for patients
for whom we had both types of data.
(PDF)
S14 Fig. Intersection between different types of molecular aberration in BRCA1 and
BRCA2. This graph indicates how many patients had each type of molecular aberration and
the level of overlap among these aberrations within a given patient. In most cases, these aberra-
tions were mutually exclusive from each other; however, some overlap did occur. For example,
one patient had a somatic mutation in BRCA1 and hypermethylation of the same gene. This
graph only depicts patients for whom all four types of molecular data were available.
(PDF)
S15 Fig. Overlap between BRCA1/BRCA2 germline-mutation status and PAM50 subtype.
Gene-expression subtypes were unavailable for some patients; One BRCA1 carrier is not repre-
sented in this figure; we could not assign a gene-expression subtype to this individual due to
missing data.
(PDF)
S16 Fig. Overlap between BRCA1/BRCA2 germline-mutation status and primary somatic-
mutation signature. This graph represents patients for whom we had both germline- and
somatic-mutation data.
(PDF)
S17 Fig. Overlap between PAM50 subtype and primary somatic-mutation signature. This
graph represents patients for whom we could evaluate the status of both PAM50 subtype and
somatic-mutation signatures.
(PDF)
S18 Fig. BRCA1 and BRCA2 aberrations on the somatic-mutation signature landscape
using multidimensional scaling. Using the same two-dimensional representation of muta-
tional signatures shown in Fig 1, this plot indicates which patients had germline mutations (A,
B), somatic mutations (C, D), homozygous deletions (E, F), or hypermethylation events (G, H)
in BRCA1 and BRCA2, respectively. Largely, these tumors had similar somatic-mutation sig-
natures. Diamond shapes indicate patients for whom no loss-of-heterozygosity was observed.
Data are shown for all patients, even those for whom we did not have all types of data.
(PDF)
S19 Fig. BRCA1 and BRCA2 aberrations on the somatic-mutation signature landscape
using the t-SNE method. Using the same two-dimensional representation of mutational
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signatures shown in S10 Fig, this plot indicates which patients had germline mutations (A, B),
somatic mutations (C, D), homozygous deletions (E, F), or hypermethylation events (G, H) in
BRCA1 and BRCA2, respectively. Largely, these tumors had similar somatic-mutation signa-
tures. Diamond shapes indicate patients for whom no� loss-of-heterozygosity was observed.
Data are shown for all patients, even those for whom we did not have all types of data.
(PDF)
S20 Fig. Euclidean distances for randomly selected patients compared to actual distances
within BRCA1/BRCA2 patient groups based on somatic-mutation signatures. We calcu-
lated the Euclidean distance between each pair of individuals who had germline mutations (A,
B), somatic mutations (C, D), homozygous deletions (E, F), or hypermethylation events (G, H)
in BRCA1 or BRCA2; the medians of these distances are illustrated using vertical, dashed lines.
We then randomized the patient identifiers and calculated pairwise distances for the same
number of randomly selected patients, which resulted in an empirical null distribution. We
calculated p-values by comparing the actual distances against the randomized distances and
then adjusted for multiple tests using Holm’s method.
(PDF)
S21 Fig. BRCA1 and BRCA2 aberrations on the gene-expression landscape using multidi-
mensional scaling. Using the same two-dimensional representation of gene-expression pro-
files shown in Fig 2, this plot indicates which patients had germline mutations (A, B), somatic
mutations (C, D), homozygous deletions (E, F), or hypermethylation events (G, H) in BRCA1
and BRCA2, respectively. Many of these tumors overlapped with the Basal-like subtype, but
other tumors were dispersed broadly across the gene-expression landscape. Diamond shapes
indicate patients for whom no loss-of-heterozygosity was observed. Data are shown for all
patients, even those for whom we did not have all types of data.
(PDF)
S22 Fig. BRCA1 and BRCA2 aberrations on the gene-expression landscape using the t-
SNE method. Using the same two-dimensional representation of gene-expression profiles
shown in S11 Fig, this plot indicates which patients had germline mutations (A, B), somatic
mutations (C, D), homozygous deletions (E, F), or hypermethylation events (G, H) in BRCA1
and BRCA2, respectively. Many of these tumors overlapped with the Basal-like subtype, but
other tumors were dispersed broadly across the gene-expression landscape. Diamond shapes
indicate patients for whom no loss-of-heterozygosity was observed. Data are shown for all
patients, even those for whom we did not have all types of data.
(PDF)
S23 Fig. Euclidean distances for randomly selected patients compared to actual distances
within BRCA1/BRCA2 patient groups based on gene-expression profiles. We calculated the
Euclidean distance between each pair of individuals who had germline mutations (A, B),
somatic mutations (C, D), homozygous deletions (E, F), or hypermethylation events (G, H) in
BRCA1 or BRCA2; the medians of these distances are illustrated using vertical, dashed lines.
We then randomized the patient identifiers and calculated pairwise distances for the same
number of randomly selected patients, which resulted in an empirical null distribution. We
calculated p-values by comparing the actual distances against the randomized distances and
then adjusted for multiple tests using Holm’s method.
(PDF)
S24 Fig. Somatic-mutation signature-based Euclidean distances for randomly selected
patient pairs compared to actual distances between patient pairs for individuals with
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BRCA1/BRCA2 aberrations. We identified patients who had a germline mutation in BRCA1
or BRCA2 and compared them against each other (A), those with a somatic mutation in the
same gene (B-C), those with a homozygous deletion in the same gene (D-E) and those with
DNA hypermethylation of the same gene (F-G). We calculated the Euclidean distance between
each pair of individuals in these groups; these distances are illustrated using vertical, dashed
lines. We then randomized the patient identifiers and calculated pairwise distances for groups
of randomly selected patients, which resulted in an empirical null distribution. We calculated
p-values by comparing the actual distances against the randomized distances.
(PDF)
S25 Fig. Gene-expression based Euclidean distances for randomly selected patient pairs
compared to actual distances between patient pairs for individuals with BRCA1/BRCA2
aberrations. We identified patients who had a germline mutation in BRCA1 or BRCA2 and
compared them against each other (A), those with a somatic mutation in the same gene (B-C),
those with a homozygous deletion in the same gene (D-E) and those with DNA hypermethyla-
tion of the same gene (F-G). We calculated the Euclidean distance between each pair of indi-
viduals in these groups; these distances are illustrated using vertical, dashed lines. We then
randomized the patient identifiers and calculated pairwise distances for groups of randomly
selected patients, which resulted in an empirical null distribution. We calculated p-values by
comparing the actual distances against the randomized distances.
(PDF)
S26 Fig. Euclidean distances for randomly selected patients compared to actual distances
across all patients with a BRCA1 or BRCA2 aberration based on somatic-mutation signa-
tures. We calculated the Euclidean distance between each pair of individuals who had a germ-
line mutation, somatic mutation, homozygous deletion, and/or hypermethylation event in
BRCA1 and/or BRCA2; the median of these distances is illustrated using a vertical, dashed
line. We then randomized the patient identifiers and calculated pairwise distances for the
same number of randomly selected patients, which resulted in an empirical null distribution.
We calculated a p-value by comparing the actual distance against the randomized distances.
(PDF)
S27 Fig. Number of patients with germline mutations in non-BRCA cancer-predisposition
genes. This graph omits genes in which we observed no germline mutations. SNV = single-
nucleotide variant.
(PDF)
S28 Fig. Non-BRCA germline mutations on the somatic-mutation signature landscape
using the t-SNE method. Using the same two-dimensional representation of mutational sig-
natures shown in S10 Fig, this plot indicates which patients had germline mutations in non-
BRCA cancer-predisposition genes. Diamond shapes indicate patients for whom no loss-of-
heterozygosity was observed.
(PDF)
S29 Fig. Number of patients with somatic mutations in non-BRCA cancer-predisposition
genes. This graph omits genes in which we observed no somatic mutations.
(PDF)
S30 Fig. Non-BRCA somatic mutations on the somatic-mutation signature landscape
using the t-SNE method. Using the same two-dimensional representation of mutational sig-
natures shown in S10 Fig, this plot indicates which patients had somatic mutations in non-
BRCA cancer-predisposition genes. Diamond shapes indicate patients for whom no loss-of-
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heterozygosity was observed.
(PDF)
S31 Fig. Number of patients with homozygous deletions in non-BRCA cancer-predisposi-
tion genes. This graph omits genes in which we observed no homozygous deletions.
(PDF)
S32 Fig. Non-BRCA homozygous deletions on the somatic-mutation signature landscape
using the t-SNE method. Using the same two-dimensional representation of mutational sig-
natures shown in S10 Fig, this plot indicates which patients had homozygous deletions in non-
BRCA cancer-predisposition genes. Diamond shapes indicate patients for whom no loss-of-
heterozygosity was observed.
(PDF)
S33 Fig. DNA methylation (beta) values for non-BRCA cancer-predisposition genes.
Tumors that we classified as having hypermethylation events are highlighted as red points.
This graph omits genes in which we observed no hypermethylation events.
(PDF)
S34 Fig. Non-BRCA hypermethylation events on the somatic-mutation signature land-
scape using the t-SNE method. Using the same two-dimensional representation of mutational
signatures shown in S10 Fig, this plot indicates which patients had hypermethylation events in
non-BRCA cancer-predisposition genes. Diamond shapes indicate patients for whom no loss-
of-heterozygosity was observed.
(PDF)
S35 Fig. Gene-expression levels for all the genes we studied. For each gene, we identified
tumors that expressed these genes at relatively low levels compared to other breast tumors;
these low expressors are highlighted as red points.
(PDF)
S36 Fig. Relationship between BRCA aberration status and relatively low gene expression.
We identified tumors with low expression for cancer-predisposition genes (see S35 Fig) and
evaluated whether the somatic-mutation signatures of these tumors were relatively similar or
dissimilar to the BRCA reference group. Each red rectangle represents a patient sample that
expressed a given gene at low levels. Low expression of RAD51C and BRCA1 showed the
strongest positive correlation between gene-expression status and the BRCAness reference
group. Low expression of BARD1 and CDH1 showed the strongest negative correlation
between gene-expression status and the BRCAness reference group. Genes for which no
tumors exhibited low expression are omitted.
(PDF)
S37 Fig. Relationship between BRCA aberration status and demographic, histopatholog-
ical, and surgical observations in breast-cancer patients. Red rectangles indicate patients
that were positive for each respective clinical characteristic. Tumors with triple-negative hor-
mone receptors, infiltrating ductal carcinoma histologies, or close surgical margins overlapped
most with BRCA-aberrant tumors based on somatic-mutation signatures.
(PDF)
S38 Fig. Relationship between BRCA aberration status and pharmacological responses in
breast-cancer patients. We evaluated clinical treatment responses for 211 TCGA patients for
whom drug-response data were available. Responses for none of the drugs were significantly
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correlated with BRCA aberration status based on somatic-mutation signatures.
(PDF)
S1 Table. Outcome of pathogenicity evaluation for somatic mutations in BRCA1 and
BRCA2. We evaluated somatic mutations in BRCA1 and BRCA2 based on variant type, pre-
dicted effects on protein sequence, evolutionary conservation, minor allele frequency, evidence
in ClinVar, etc. This table provides information about each variant and specified criteria that
we considered. A value of 1 in the Pathogenicity column indicates that we considered the vari-
ant to be pathogenic in our analyses.
(DOCX)
S2 Table. Summary of classification analysis for predicting a tumor’s aberration status.
Via cross validation, we used gene-expression profiles and somatic-mutation signatures,
respectively, to predict whether a given patient/tumor harbored particular types of aberrations.
Sensitivity is equivalent to the true-positive rate. Specificity is equivalent to the true-negative
rate. The area under the receiver operator characteristic curve (AUROC) quantifies the balance
between sensitivity and specificity across a range of prediction thresholds.
(DOCX)
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